Piramal Pharma (PPLPHARMA.BO) Earnings Analysis
Piramal Pharma (PPLPHARMA.BO) has no confirmed upcoming earnings date. Last quarter (2026-01-28) it missed with EPS -0.7 INR vs -0.05 INR est (-1300%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -73.42.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PPLPHARMA.BO next report earnings?
No confirmed upcoming earnings date is currently scheduled for PPLPHARMA.BO. This page updates as the calendar is published.
PPLPHARMA.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-01-28 | -0.7 INR | -0.05 INR | -1300% | Miss |
| 2025-07-25 | -0.62 INR | -0.685 INR | +9.5% | Beat |
| 2025-01-28 | 0.03 INR | 1.25 INR | -97.6% | Miss |
| 2024-10-23 | 0.17 INR | n/a | n/a | n/a |
| 2024-07-26 | -0.67002 INR | 0.73 INR | -191.8% | Miss |
Beat rate: 1/4 (25%) over reported quarters with consensus data.
PPLPHARMA.BO valuation and analyst view
| Trailing P/E | -73.42 |
|---|---|
| Trailing EPS | -2.58675 INR |
| Price / book | 2.80 |
| Dividend yield | 0.08% |
| Market cap | 235.14B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Piramal Pharma (PPLPHARMA.BO)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for PPLPHARMA.BO. This page updates as the calendar is published.
Did PPLPHARMA.BO beat earnings last quarter?
In its 2026-01-28 report, PPLPHARMA.BO posted EPS of -0.7 INR versus a -0.05 INR estimate — a miss of 1300%.
What is PPLPHARMA.BO's earnings track record?
Over the last 4 reported quarters with consensus data, PPLPHARMA.BO beat estimates 1 times (25%).
What is PPLPHARMA.BO's current P/E ratio and EPS?
PPLPHARMA.BO trades at a trailing P/E of -73.42 on trailing EPS of -2.586746031746032 INR.
What do analysts rate PPLPHARMA.BO?
PPLPHARMA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.